Media
You are currently on our Canadian website.
Visit our international website at: pharmalabiotech.com
Press Releases
Please note, all press releases older than a year can be found at https://www.sedarplus.ca/
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002
Posted: Jul 05, 2026
CEO Letter To Shareholders
Posted: Jun 18, 2026
PharmAla Biotech Annual General Meeting Materials
Posted: Jun 08, 2026
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
Posted: May 20, 2026
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
Posted: May 12, 2026
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
Posted: Apr 27, 2026
PharmAla Issues Q2 Financial Statements and Grants Options
Posted: Apr 21, 2026
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
Posted: Apr 20, 2026
Cortexa Advances Commercialisation of MDMA Supply in Australia
Posted: Mar 23, 2026
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
Posted: Mar 03, 2026
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
Posted: Feb 25, 2026
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
Posted: Feb 22, 2026
PharmAla Announces Changes to Board of Directors
Posted: Feb 10, 2026
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
Posted: Jan 08, 2026
PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements
Posted: Dec 23, 2025
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
Posted: Dec 15, 2025
PharmAla Biotech Completes Release Testing on Australian-Made LaNeo Capsules
Posted: Dec 10, 2025
PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
Posted: Nov 03, 2025
PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists
Posted: Oct 08, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
Posted: Oct 02, 2025
PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand
Posted: Sep 25, 2025
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
Posted: Sep 19, 2025
PharmAla Completes Import of LaNeo MDMA for U.S Distribution
Posted: Sep 08, 2025
PharmAla Incorporates Australian Entity for Clinical Research
Posted: Sep 03, 2025
PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
Posted: Aug 07, 2025
PharmAla Issues Q3 Financial Statements
Posted: Jul 25, 2025
Search Releases
Type keywords to filter the list of press releases:
Media Inquiries
Nicholas Kadysh, CEO
press@pharmala.ca
PharmAla's Earning & Financial Webinar
A Discussion On: Third Party Insurance for Psychedelic Assisted Therapy
PharmAla Biotech Investors Webinar
MDMA: Real World Efficacy Explored
FDA: Guidance | A Discussion On Psychedelic Regulations Globally
Optimizing Clinical Trial Design and The State of the Market
'Cortexa' explained. A Discussion on PharmAla Biotech and Vitura Health Limited Recent JV
Psychedelics Today: Manufacturing MDMA and Why Creating MDMA Analogs Is So Important
The Dales Report - Pharmala Stock Succeeds Through Tough Markets
Changes Announced By The TGA & What It Means For Psychedelics Webinar
PharmAla Biotech | Planning Psychedelic Trials & Navigating the Import/Export Process Webinar
PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia
PharmAla Biotech signs supply deal with Global Wellness Strategies to provide MDMA for trial
Psychedelics 101 | February 8, 2022
Rick Doblin, Exec. Director, MAPS & Nick Kadysh, President & CEO, PharmAla Biotech | MDMA Conference